Dr. Carol Adelman, director of the Center for Global Prosperity at the Hudson
Institute, publishes the annual Index of Global Philanthropy, a guide to private
philanthropy and remittance flows abroad. She served as an Assistant Administrator
at USAID in charge of foreign aid to Asia, the Middle East and Eastern Europe. Dr.
Adelman was vice chair of the H.E.L.P Commission, a bipartisan commission to
reform foreign aid, and is vice chair of an advisory committee to USAID. She writes
on global philanthropy and economic development in The New York Times, Foreign
Affairs, Wall Street Journal, International Herald Tribune, and technical journals. Dr.
Adelman is a vice chairman of the Atlantic Council and member of the Council on
Foreign Relations. She holds a doctorate in Public Health from Johns Hopkins
University, a Masters in Foreign Service from Georgetown University, and a B.A. from the University of Colorado.

Jorge Amigo has a BA in economics from Anahuac University and an MA from the
University of the Americas. Between 1970 and 1984, he was Relations Manager at
the Banco de Comercio, Marketing Manager for Jeffrey Manufacturera Mexicana, a
material handling manufacturer and General Manager of Menite Metal de México, an
iron foundry. He entered public service in 1984, with positions including Director of
Economic Evaluation at the Ministry of Commerce (1986); Technical Secretary of the
National Foreign Investment Commission (1989); Director General of Foreign
Investment (1990-1992). In 1993, he became Director General of Technological
Development of the Ministry of Commerce and in 1994, Mr. Amigo was appointed by
President Ernesto Zedillo to his current position as Director General of the Mexican
Institute of Industrial Property. Mr. Amigo headed the Mexican delegation for the
negotiation of the Investment Chapter of the North American Free Trade Agreement
(NAFTA). Since 1993, he has been Head of the Mexican delegation for intellectual
property matters, in negotiations of Free Trade Agreements and in fora such as
WIPO, FTAA and APEC. In all of the latter bodies, he has been elected or appointed
to leadership positions. He is a member of the National College of Economists,
teaches at his alma mater and has published extensively.

Paul Antony, MD, MPH is Chief Medical Officer at the Pharmaceutical Research and
Manufacturers of America (PhRMA), and is its principal advocate on all health care
and medical policy issues. Dr. Antony is board-certified by the American Board of
Preventive Medicine and joined PhRMA after serving in the U.S. Navy as Flight
Surgeon and Senior Medical Officer for the Marine One Presidential Helicopter
Squadron. He received his Doctor of Medicine and Master of Public Health degrees
from the George Washington University Medical Center and now serves on its faculty
in the department of Microbiology, Immunology, and Tropical Medicine. Prior to
attending medical school, he earned an MBA from Harvard Business School, and
received a Bachelor of Science degree in biomedical engineering from Johns Hopkins
University. Dr. Antony was a 1993-1994 White House Fellow serving in the Executive
Office of the President. He continues to treat patients as a reservist in the U.S. Navy
and is a member of the American Medical Association and the American College of
Preventive Medicine.

Rich Bagger heads Worldwide Public Affairs and Policy for Pfizer, with responsibility
for public policy, government relations, international public affairs, corporate
responsibility, philanthropy and stakeholder advocacy. Prior to joining Pfizer in 1993,
he was Assistant General Counsel of Blue Cross and Blue Shield of New Jersey, and
practiced law with McCarter and English. He was Chairman of the Appropriations
Committee and Majority Conference Leader in the New Jersey General Assembly. In
2001, he was elected to the New Jersey Senate and served there until 2003. He is
Chairman of the Board of Trustees of the Healthcare Institute of New Jersey, and
serves on the Board of Trustees of the United States Chamber of Commerce, the New
Jersey Performing Arts Center, the United Hospital Fund, Kean University and the
Westfield United Way. He received an A.B. degree from Princeton University’s
Woodrow Wilson School of Public and International Affairs and a J.D. degree from
Rutgers University Law School.

Dr. Banchi joined the Boehringer Ingelheim Italian organisation in the marketing and
sales department in 1973. He worked for BI USA Corporation 1985 to1986 and the
returned to Italy, where he was appointed Managing Director of Boehringer Ingelheim
Italia S.p.A in 1991. From 1992 he headed Boehringer Ingelheim Group in Italy as
Country Manager. Since January 1st, 2000 he has been a Member of the Board of
Managing Directors of Boehringer Ingelheim, responsible for the Corporate Board
Division Pharma Marketing and Sales. As of January 1st, 2004 he became Chairman
of the Board of Managing Directors. At the moment, Dr. Banchi is Vice-President of
the Council of IFPMA (International Federation of Pharmaceutical Manufacturers &
Associations ) and Member of the Board of EFPIA (European Federation of
Pharmaceutical Industries and Associations).

Richard is Director General of the Association of the British Pharmaceutical Industry,
and a board member of EFPIA and council member of IFPMA. His priorities include
boosting the UK and Europe as a global leader in pharmaceutical innovation,
strengthening the partnership between the industry and the Health Service,
increasing patient engagement and access to new medicines in the UK and globally,
and ensuring that the industry’s external image reflects its major contribution to
health and economic prosperity. He is Chairman of Stem Cells for Safer Medicines, a
public-private partnership developing stem cell technology for predicting the safety
profile of new medicines. He is a Board member of Datapharm Communications, a
company bringing on-line medicines information to UK prescribers and patients. He is
also a member of the Ministerial Strategy Group for the industry, the NHS National
Leadership Network and Stakeholder Forum, and Vice-Chairman of the UK Clinical
Research Consortium and of its Advisory Board on Connecting for Health. He is a
stakeholder in the TB Alliance, which is developing new medicines for this
devastating condition.

Thomas R. Barker is Acting General Counsel of the US Department of Health and
Human Services (HHS), overseeing all legal matters affecting HHS and its agencies,
including the Centers for Medicare & Medicaid Services (CMS); the Food and Drug
Administration (FDA); the Office of the National Coordinator for Health Information
Technology, (ONC); and the Office of Civil Rights (OCR). Mr. Barker supervises a
staff of 450 attorneys and is responsible for the legal accuracy of all regulations
issued by the Department and its agencies, and the conduct of all litigation to which
the Department is a party. Prior to assuming this role in May 2008, he was senior
policy advisor to the Secretary of HHS from 2005, Deputy General Counsel of HHS,
responsible for the CMS Division of OGC (2003-05) and Health Policy Counselor to
the Administrator of CMS (2001-03). From 1992-2001, Mr. Barker was a health policy
analyst and regulatory counsel for the Massachusetts Hospital Association. Mr.
Barker is also an assistant professor of health law at the George Washington
University School of Public Health and Health Services in Washington, D.C. and a
member of the adjunct faculty of Suffolk University School of Law. He teaches
courses in Medicare and Medicaid law; tax law issues in health care; and introductory
health law.

Richard Bergstrom has an MScPharm from the University of Uppsala, Sweden. Until
1992 he worked at the Medical Products Agency as Assistant Head of Registration.
He then worked for nine years ins Switzerland in regulatory affairs at Roche and
Novartis. Currently, he is Director-General of LIF, the Swedish Association of the
Pharmaceutical Industry, Member of the Board of the European association EFPIA,
and of the Council of the IFPMA. Mr Bergstrom is particularly involved in policies
relating to health technology assessment (HTA) and marketing codes. In the latter
area he serves as chair of the IFPMA Code Compliance Network and chair of the
EFPIA Code Steering Committee. In Sweden, he has been appointed by the
Government to the Board of the Karolinska Institute. He has also been appointed
advisor to the World Health Organization in Geneva in the project for good
governance in the health sector.

Born in Austria in 1944, Peter Brabeck-Letmathe completed his studies in Economics
at the University of World Trade in Vienna and joined Nestlé Austria in 1968. His
international career included almost 10 years in Chile. In 1981, he was appointed
Managing Director of Nestlé Ecuador, in 1983, President and Managing Director of
Nestlé Venezuela. In 1987, he transferred to the international headquarters as Senior
Vice President responsible for the Culinary Products Division. In 1992 he was
appointed Executive Vice President of Nestlé S.A. with worldwide leadership of
strategic business groups while simultaneously being in charge of Marketing,
Communications and Public Affairs. At the Ordinary General Meeting of Shareholders
in 1997, he was elected Member of the Board of Directors and CEO of Nestlé S.A. In
2001 he was elected Vice-Chairman of the Board, in 2005 Chairman of the Board
and in 2008, he handed over the office of CEO and is now Chairman of Nestlé S.A.

Craig Brammer is Senior Research Associate with the Institute for the Study of
Health at the University of Cincinnati Academic Health Center, where he is currently
Director of Aligning Forces for Quality: The Regional Market Project (Cincinnati, OH),
one of 14 in the United States to align incentives, engage consumers and measure
performance for improving healthcare quality. Mr. Brammer recently served as
Principal Investigator in studies to assist the Ohio Department of Jobs and Family
Services in the design of Ohio Medicaid’s pay-for-performance (P4P) strategy,
including evaluating metrics for appropriateness in Medicaid, surveying health plans
on their P4P approach, and working with physicians and other stakeholders on P4P
design characteristics. He previously authored studies for the Institute of Medicine,
National Rural Health Association and others on performance measurement and
practice redesign. Mr. Brammer is Co-Director of the Humana/University of Cincinnati
Physician Leadership Program; Co-Principal Investigator for multiple grants and
projects on medical education in healthcare improvement at the University of
Cincinnati; and leads the Institute’s Health Policy Forum seminar series.

Senator John Breaux’s career in Congress began when he was elected to the House
of Representatives in 1972 at the age of 28, for the 7th District of Louisiana, and was
elected to fill Senator Russell Long’s seat in 1986. Senator Breaux was a recognized
bipartisan leader and in 1993 was elected Democratic Deputy Minority Whip, a
position he held until his retirement. A senior member of the Finance Committee,
Senator Breaux served as the Chairman of the Subcommittee on Social Security and
Family Policy. He also held positions on the Subcommittees on Health Care and on
Taxation and IRS Oversight. On the Finance Committee, he helped pass welfare
reform and health insurance reform bills, reduce capital gains tax and provide tax
relief for college education expenses. As Chairman of the Special Committee on
Aging, Senator Breaux helped protect and strengthen Social Security, Medicare, and
other programs. In 1998 he was selected to chair the National Bipartisan Commission
on the Future of Medicare. Also in 1998, Senator Breaux co-chaired the National
Commission on Retirement Policy, which produced legislation to help reform Social
Security. He served as Co-Chair of the Oil and Gas Caucus and helped write the
2005 Energy Bill. Senator Breaux was active in advancing legislation to promote
domestic oil and gas production, and was a Co-Sponsor of the Marginal Well
Preservation Act, a tax-incentive program to encourage oil production from marginal
oil wells. He was also a principal author of the Outer Continental Shelf Land Act.
Senator Breaux was a founder of the Centrist Coalition of Senate Democrats and
Republicans and served as Chairman of the Democratic Leadership Council. In 2005
President George W. Bush appointed Senator Beaux as the Co-Chair of the
President’s Advisory Panel on Federal Tax Reform. Upon retirement from the Senate
in 2005, Senator Breaux joined Patton Boggs as Senior Counsel. In 2008, Senator
Breaux joined forces with former Senator Trent Lott to form the Breaux Lott
Leadership Group, providing advice on public policy matters, especially health care
and energy.

Dr. Shing Chang joined DNDi as R&D Director in October 2007. In this position he is
responsible for building DNDi’s project portfolio and advance the discovery and
development of new treatments for neglected diseases. Prior to joining DNDi, Dr.
Chang was Senior Vice President, Drug Discovery and Chief Scientific Officer at
ICOS Corporation. From 1991 to 2006, Dr. Chang held various management
positions at Abbott Laboratories in diagnostics and pharmaceutical research,
including 7 years as Divisional Vice President, Infectious Disease Research. In 1978,
he joined Cetus Corporation as one of its first molecular biologists. Dr. Chang held
various positions at Cetus including Vice President, Preclinical and Development, a
position he held until 1991. Dr. Chang completed post doctoral fellowships at the
University of Wisconsin and Stanford University. He received his Ph.D. in molecular
biology and biochemistry from the University of California, Santa Barbara and his
Bachelor of Science in biology from Fu-Jen Catholic University in Chinese Taipei.

Richard T. Clark has been President and CEO of Merck & Co., Inc. since May 2005,
and Chairman of the Board since April 2007. Mr. Clark joined Merck in 1972 as a
Quality Control Inspector, and progressed through a series of increasingly
responsible roles in production, new products planning, industrial engineering and
management engineering, becoming Vice President, Materials Management and
Management Engineering in 1991. In 1993, Mr. Clark was appointed Vice President,
Procurement and Materials Management. He became Vice President of North
American Operations for the Merck Manufacturing Division in 1994 and Senior Vice
President in 1996. In 1997, he was appointed Senior Vice President of Quality and
Commercial Affairs. Later that year, Mr. Clark joined the Merck-Medco Managed
Care subsidiary as Executive Vice President and Chief Operating Officer. He later
served as Chairman, President and Chief Executive Officer of the newly named
Medco Health Solutions, overseeing plans to prepare that organization to become a
publicly traded company. He returned to the Merck Manufacturing Division as
President in June 2003. In April 2008, Mr. Clark was elected board chairman of the
Pharmaceutical Research and Manufacturers of America (PhRMA), which represents
the country’s leading pharmaceutical research and biotechnology companies. Mr.
Clark earned his bachelor’s degree in Liberal Arts from Washington & Jefferson
College, and his M.B.A. from American University. He served as a Lieutenant in the
U.S. Army from 1970 to 1972 before joining Merck.

Chantal Compaoré, First Lady of Burkina Faso, is the wife of Blaise Compaoré who
became President in 1987. She is active in Burkina Faso and Africa, leading
philanthropic activities to help women and children, and to fight HIV/AIDS. Mme
Compaoré created the Suka Foundation in 1999 to help children, notably thought the
SOS Children village in Ziniaré, in which CFA 500 million has been invested to date.
Suka also helps vaccinate against polio and tetanus, and works to increase tolerance
for maladjusted children. Mme Compaoré has also been a driving force behind the
building of schools. Mme Compaoré is honorary president of Synergies Africaines, an
association of African First Ladies which works to diminish the impact of HIV/AIDS
within the continent. Synergies helps patients to live with their disease, and
encourages them to use experiences to help educate others about its dangers. The
Suka Foundation also helps with prevention of mother-to-child transmission of
HIV/AIDS, and also helps to treat children with AIDS. Mme Compaoré is also active
on behalf of the Biya Foundation, which works to increase HIV testing. Mme
Compaoré also strives to improve the lives of women. In 2005, she created a
women’s house in Balé for vulnerable women, and she works to improve girls’
literacy, to motivate parents to educate their daughters and to encourage better
treatment of women. She also helps the Karité organization to provide assistance to
underprivileged women.
Thomas

Thomas B. Cueni is Secretary General of Interpharma, the association of the Swiss
pharmaceutical research companies. Mr. Cueni is a member of the Board of the
European Federation of the Pharmaceutical Industries’ Associations (EFPIA) and is
on various committees of the IFPMA. Mr. Cueni also serves on the Swiss Federal
Medicines Committee, an advisory body to the Swiss Government. Prior joining
Interpharma, Mr. Cueni worked as a journalist for two Swiss newspapers. In 1983,
Mr. Cueni joined the Swiss Foreign Service as a career diplomat with postings in
Vienna at the Swiss Mission to the United Nations, the International Atomic Energy
Agency, and the United Nations Industrial Development Organisation, and in Paris,
where he was a member of the Swiss Delegation to the OECD. Mr. Cueni has a
degree in economics (University of Basle) and a post-graduate degree in politics
(M.Sc.) from the London School of Economics.

Vicki Ehrich is Chief Operating Officer of the Pharmaceutical Industry Association of
South Africa (PIASA), representing multinational and local pharmaceutical
companies. As COO of the former Pharmaceutical Manufacturers’ Association
since February 2004, Vicki helped form PIASA, which is a member IFPMA. Before
that, Vicki was Director, Corporate Affairs, at GlaxoSmithKline South Africa,
responsible for government affairs, external communications, internal
communications, community relations and corporate social investment. During her
15 years with GSK, Vicki held various positions including Marketing Director,
Director of Business Development and, more recently, Director of Corporate Affairs.
Vicki also spent 2 years with GSK Corporate Communications in the UK, as
Director, External Affairs HIV/AIDS, responsible for the Positive Action Programme,
supporting communities affected by HIV/AIDS, and was extensively involved in
access to medicines issues. Vicki has worked for four pharmaceutical companies,
ranging from multinationals to South African generic companies. Vicki has a BCom
(Hons) degree from the former University of Port Elizabeth now Nelson Mandela
Metropolitan University.

Alicia Greenidge was appointed Director General of the IFPMA in June 2008. She has
more than 15 years experience in bilateral and multilateral negotiations with
governments in the Americas, Africa, Asia, Pacific, Middle East, and Europe, working
largely for the Office of the United States Trade Representative in Washington and in
Geneva. She served as Assistant Deputy Chief of Mission and Senior Counsel in
Geneva for the last 8 years. She contributed to many settlements before the World
Trade Organization, notably the Public Health Declaration and subsequent agreements
concerning local pharmaceutical manufacturing in developing countries. She also
worked on issues on the relationship between the Trade Related Intellectual Property
Rights Agreement (TRIPS), and the Convention on Biodiversity and agreements on
Least Developed Country matters under TRIPS. Since 1998, she also has interacted
with, and advised on issues before, other inter-governmental organizations, such as
WHO (including infant formula, health personnel, IGWG issues and the IGM on virus
sharing and access to vaccines), UNAIDS, WIPO, UNCTAD and others. In addition,
she has engaged constructively with several non-governmental organizations in
Geneva. She has a Juris Doctorate from Boston College, a Master’s degree in Public
International Law & International Development Economics from the American
University, and a Bachelor’s degree in International Relations and Sociology from C.W.
Post College/LIU.

Fred Hassan is chairman of the board and chief executive officer of Schering-Plough
Corporation. He was elected President of the IFPMA in October 2006. Prior to joining
Schering-Plough in April 2003 and assuming his current position, Mr. Hassan was
chairman and chief executive officer of Pharmacia Corporation. He joined the former
Pharmacia & Upjohn in May 1997 as chief executive officer and was elected to the
Board of Directors. In February 2001, Mr. Hassan was named chairman of the Board
of Pharmacia. Previously, Mr. Hassan was executive vice president of Wyeth,
formerly known as American Home Products, with responsibility for its
pharmaceutical and medical products business. He was elected to Wyeth’s Board of
Directors in 1995. Mr. Hassan also spent 17 years with Sandoz Pharmaceuticals
(now Novartis) and headed its U.S. pharmaceuticals business. He is the past
chairman of the Board of Directors of the Pharmaceutical Research and
Manufacturers of America (PhRMA) and is the immediate past chairman of the
HealthCare Institute of New Jersey.

Karen Ignagni is President and Chief Executive Officer of America’s Health Insurance
Plans (AHIP), representing members that provide health care, long-term care, dental
and disability benefits to more than 200 million Americans. AHIP was formed in 2003
after a merger of the Health Insurance Association of America and the American
Association of Health Plans. Ms Ignagni led the latter body since 1993. Ranked by
the Hill Newspaper as one of Washington’s most effective lobbyists, Ms. Ignagni
regularly testifies before Congress and has published numerous articles. Prior to
joining AAHP, Ms. Ignagni directed the AFL-CIO’s Department of Employee Benefits.
In the 1980s, she was a Professional Staff Member on the U.S. Senate Labor and
Human Resources Committee, preceded by work at the Committee for National
Health Insurance and the U.S. Department of Health and Human Services.

Professor Michel D. Kazatchkine became Executive Director of the Global Fund to
fight AIDS, tuberculosis and malaria in 2007. He has spent the past 25 years fighting
AIDS as a leading physician, researcher, administrator, advocate, policy maker, and
diplomat. He studied at Necker-Enfants-Malades, Paris, the Pasteur Institute, St
Mary’s hospital, London and Harvard Medical School, and was Professor of
Immunology at Université René Descartes and Head of the Immunology Unit of the
Georges Pompidou Hospital in Paris. He has authored or coauthored of over 500
articles, on subjects such as auto-immunity, immuno-intervention and pathogenesis
of HIV/AIDS. Dr. Kazatchkine was Director of the National Agency for Research on
AIDS (ANRS) in France (1998-2005), French Ambassador for HIV/AIDS and
communicable diseases (2005-2007), Vice-Chair of the Board of the Global Fund
(2005-2006), first Chair of the Technical Review Panel of the Global Fund (2002-
2005), Chair of the WHO’s Strategic and Technical Advisory Committee on HIV/AIDS
(2004-2007), and a member of the WHO’s Scientific and Technical Advisory Group
on tuberculosis (2004-2007). While recognizing the enormous challenges of tackling
HIV/AIDS, tuberculosis and malaria globally, Dr. Kazatchkine believes that the
progress made in recent years, particularly through programs supported by the
Global Fund, presents enormous opportunities. He also emphasizes the importance
of partnerships.

Hannah Kettler is an economist and senior program officer on the Global Health
Advocacy team at the Bill and Melinda Gates Foundation. She is responsible for
projects to secure adequate financing and a supportive policy environment for global
health product innovation and introduction. Much of her work is focused on designing
of financial incentives and business models to encourage greater private sector
company engagement. Prior to joining the Gates Foundation in 2003, Hannah led a
two year Rockefeller Foundation funded project titled “Biotechnology and Global
Health” at the Institute for Global Health at the University of California San Francisco.
The work motivated BIO and the Bill and Melinda Gates Foundation to establish
BioVentures for Global Health in 2004. Between 1998 and 2001 Hannah worked as
the Senior Industrial Economist for the Office of Health Economics (OHE) in London.
Hannah has a PhD in Industrial Economics from the University of Notre Dame.

William Kingsmill is currently Acting Director of the Policy and Research Division of
the UK government’s Department for International Development (DFID) based in
London. Prior to this he held the post of Head of DFID’s Growth and Investment
Group and was Head of DFID’s office in Nigeria. Previous posts he has held in DFID
have included Head of Private Sector Policy Department and Head of Economic
Policy and Research Department. He has worked for DFID in the Caribbean and in
East Africa. He has also worked for the European Commission, working on the
design and implementation of the Euro-Mediterranean Partnership, and for the
Government of Botswana as an Economic Adviser.

Elaine Leavenworth serves as Vice President, Government Affairs for Abbott, a
global, broad-based health care company. She is responsible for International,
Federal and State efforts to identify, assess and address regulatory, administrative
and legislative proposals and actions that will impact the company and patients.
Leavenworth joined Abbott in 1991 and has held various commercial management
positions in Abbott’s Nutrition, International and Health Systems divisions. She was
elected to her position as a corporate officer in July 1999. Prior to joining Abbott,
Leavenworth was a principal with the consulting firm Louden & Company, where her
work focused on marketing and strategy assignments for health care providers,
suppliers, investors and associations. While at Louden & Company, she also
published numerous articles and several books on the health care market.
Leavenworth also held marketing positions at G.D. Searle & Co. and American
Hospital Supply Corporation.

John Lechleiter, Ph.D., was named president and chief executive officer of Eli Lilly
and Company in April 2008. John earned a bachelor of science degree in chemistry
at Xavier University (Cincinnati) and master’s and doctoral degree in organic
chemistry at Harvard University. He joined Lilly in 1979 as a senior organic chemist
and subsequently held a number of management positions in Lilly Research
Laboratories. He is a member of the American Chemical Society. In 2004, he was
appointed to the Visiting Committee of Harvard Business School and to the Health
Policy and Management Executive Council of the Harvard School of Public Health.
He also serves as a member of the Board of Trustees of Xavier University. In
addition, he is a distinguished advisor of The Children’s Museum of Indianapolis, a
member of the board of directors and executive committee of Fairbanks Institute, and
a member of the United Way of Central Indiana board of directors. He also serves on
the board of Indianapolis Downtown, Inc.

Klaus Leisinger is Chief Executive Officer and President of the Board of Trustees of
the Novartis Foundation for Sustainable Development, which has consultative status
with the Social and Economic Council of the United Nations. In addition, he is
Professor of Sociology at the University of Basel where he teaches business ethics,
Corporate Social Responsibility, as well as Human Rights and Business. Leisinger
served as guest professor at several Swiss and German universities, as well as at
the University of Notre Dame, the MIT Sloan School of Management (Cambridge),
and Harvard University. He is a member of the European Academy of Sciences and
Arts. Leisinger has held advisory positions in the United Nations Global Compact, the
United Nations Development Program (UNDP), the World Bank (CGIAR), Asian
Development Bank as well as Economic Commission for Latin America (ECLA).
Among others, he chairs of the Board of Trustees of the German Network Business
Ethics. Leisinger served as “Special Advisor of the United Nations Secretary General
for the UN Global Compact” for Kofi Annan, 2005-07.

Since 1998, Bernard Lemoine has been Executive Vice President of the French
pharmaceutical industry association, which is now known as Les Entreprises du
Médicament (LEEM). From 1979 to 1988, he was International Affairs Director, then
Deputy Director General of Fournier Laboratories. Bernard Lemoine is a member of
the Council for the Future of Health Insurance, of the French Health Care System
Accounts Commission, of the Council for Transparency in Health Insurance
Statistics, and a board member of the European Federation of Pharmaceutical
Industries and Associations and IFPMA. Dr. Lemoine has been instrumental in
creating the public-private architecture for pharmaceutical regulation which has made
of France the leading market for medicines in Europe. He has a Doctorate in Law
and a PhD in Management.

In 2007, US Senator Trent Lott left the US Congress where he worked for the people
of Mississippi for 35 years. As the House Republican Whip in 1981, he forged the
bipartisan alliance that enacted President Ronald Reagan’s economic recovery
program and his national security initiatives. Elected to the Senate in 1988, he
opposed the tax increase forced on President Bush in 1990. Becoming Senate
Majority Leader in 1996, with House Speaker Newt Gingrich, he enacted his historic
welfare reform bill of 1996. The next year, Lott, Gingrich and congressional Budget
Committee chairmen John Kasich and Pete Domenici together produced an historic
budget and tax cut agreement that limited some federal spending. As the Republican
Leader during the first two years of President George W. Bush’s administration,
Senator Lott led the fight for passage of the President’s tax cut package, the
President’s landmark education reform bill, the largest increase in defense spending
since the Cold War, the most significant trade legislation in a decade, and the
resolution supporting the President on military action in Iraq. During the Senate’s
lame duck session of November 2002, Senator Lott, drawing on his experience as a
legislative negotiator, reached the compromises that created the Department of
Homeland Security. In 2006, Senator Lott was elected Senate Republican Whip for
the second time in his career. He is the only member of Congress to hold this
position in both the House and Senate. After his retirement from the United States
Senate, Senator Lott founded the Breaux Lott Leadership Group with former Senator
John Breaux of Louisiana, a partnership offering strategic advice, consulting and
lobbying.

Dr. Mark B. McClellan became Director of the Engelberg Center for Healthcare
Reform at the Brookings Institution in 2007 and also holds the Leonard D. Schaeffer
Chair in Health Policy Studies. He was administrator for the Centers for Medicare and
Medicaid Services (2004-2006) and commissioner of the Food and Drug
Administration (2002-2004). He served on the President’s Council of Economic
Advisers and was senior director for health care policy at the White House (2001–
2002). Dr. McClellan was associate professor of economics and associate professor
of medicine (with tenure) at Stanford University, directing its Health Outcomes
Research program and was associate editor of the Journal of Health Economics, and
co-principal investigator of the Health and Retirement Study (HRS). He is a Member
of the Institute of Medicine of the National Academy of Sciences, a Research
Associate of the National Bureau of Economic Research, and a Visiting Scholar at
the American Enterprise Institute. A graduate of the University of Texas at Austin, Dr.
McClellan earned his M.P.A. from Harvard’s Kennedy School of Government, his
M.D. from the Harvard-MIT Division of Health Sciences and Technology, and his
Ph.D. in economics from MIT. He completed residency training in internal medicine at
Brigham and Women’s Hospital, Boston, has been board-certified in Internal
Medicine and has been a practicing internist.

Mr. Haruo Naito has been President and CEO of Eisai Co., Ltd. of Japan since 1988
and instituted the company’s new strategic orientation focusing on active participation
in numerous facets of human health care delivery systems. Under his leadership,
Eisai has established a global strategic research network, consisting of research
centers in the USA, Europe and Asia. In addition, Eisai now has business activities in
some forty countries throughout the world. Mr. Naito currently serves on
Northwestern University’s Kellogg Advisory Board and Duke University’s Fuqua
Board of Visitors. He also serves as Vice President of the International
Pharmaceutical Manufacturers & Associations (IFPMA). In April 1999, he was
awarded an honorary CBE by the United Kingdom in recognition of his long-standing
efforts in strengthening UK – Japan relations.

Dr. Richard Nduhuura is a Veterinary Doctor and has been Minister of State for
Health, General Duties, in the Government of Uganda since June 2006. Prior to his
current appointment, he served as Minister of State for Industry and Technology
(2001–2003), Minister of State for Trade (2003–2005) and Minister of State for Local
Government (2005–2006). Since 2001, he has represented the Igara East
Constitituency in the Bushenyi District of South Western Uganda as its Member of
Parliament. He has served both as Secretary General and Chairman of the Uganda
National Farmers Association. During his professional career, he has practiced as a
Veterinary Officer in both public and private sectors and has lectured at the
Veterinary Training Institute in Entebbe, Uganda. His current task is to ensure the
functionality of general hospitals and effective collaboration with institutions related to
the health sector. He is also tasked with setting up of a National Insurance Scheme
to ensure affordable and equitable access to health in the country.

Prof. Peter Nyong’o is currently the Minister for Medical Services in the Government
of Kenya, having previously served as Minister for Planning and National
Development. He was first elected to the Kenyan Parliament in 1992 and has been a
Member of Parliament since then, first as an opposition back-bencher (1992 – 2002)
and then as Minister. He is a Political Scientist with a Ph. D. (1977) from the
University of Chicago and has published extensively on the political economy of
development, state and social classes, democracy and democratization in Africa. His
latest book, “A Leap Into the Future”, is an analysis of the political economy of
development in Kenya and prospects for “catching up” with the developed world.

Gilles V.J. Pajot is Chief Operating Officer of IMS Health responsible for business
operations and leveraging IMS’ capabilities, offerings and services worldwide. Named
to this position in January 2007, he previously served as Executive Vice President
and President, Global Business Management for one year. Prior to that, he was
Executive Vice President and President, Europe, Middle East and Africa. Pajot joined
the company in December 1997 as Vice Chairman of IMS and President of IMS,
Europe. Previously, he was Senior Vice President of Pharmacia & Upjohn’s Europe,
Middle East and Africa Region. He also served on the merger team that formed
Pharmacia & Upjohn in 1995. In more than 23 years at Pharmacia AB, Pajot held
various positions running its subsidiaries in France from 1979 to 1990, and serving as
CEO and President of Global Pharmacia Biosystems AB 1990 to 1991. A French
national, Pajot holds a Master’s in Biochemistry and Chemistry from Rennes
University and a BSc. degree from Nantes University.

Dr. Peeling is the Research Coordinator for the UNICEF/UNDP/World Bank/WHO
Special Programme on Research and Training in Tropical Diseases (TDR), based in
the World Health Organization in Geneva, Switzerland. Trained as a medical
microbiologist, Dr. Peeling had been in charge of Diagnostics R&D in TDR and the
Canadian National Laboratory for Sexually Transmitted Diseases before assuming
her current position. She is the author of over 100 peer-reviewed publications,
authoritative reviews and book chapters. She has a strong interest in ethical issues
associated with conducting research in developing countries and was appointed the
Chair of the WHO Research Ethics Review Committee 2004-6. She was the recipient
of a YM-YWCA Women of Distinction Award, a 5NR Award for Canadian Leaders of
Sustainable Development. Her research was featured in a Discovery Channel
documentary on Chlamydia infection and infertility, and in Fighting Syphilis, a
documentary in the highly acclaimed BBC Kill or Cure series.
Swati

Dr Swati Piramal, Director, Piramal Healthcare Ltd, is responsible for the company’s
R&D, Strategic Alliances, Communications, Knowledge Management & Public Policy.
As Vice Chairperson, Piramal Life Sciences Ltd, which has a pipeline of 14 NCE’s in
diabetes, cancer, infectious disease and inflammation, she oversees Strategic
Research Planning, Discovery Research and Clinical Research. Dr Piramal has
authored papers on Drugs Price Control; Biotechnology Regulation on Biosimilars;
Data Protection Laws & Patentability and co-authored books on nutrition &
philosophy, and is the recipient of the Chevalier de l’Ordre National du Merite (2006),
BMA Management Woman Achiever (2004-05), Science & Technology National
Leadership (2006), Rajiv Gandhi Award for Outstanding Woman Achiever (2007) and
Distinguished Scientist Oration, Ministry of Science & Technology (2008); She is a
strong proponent of Intellectual Property. Piramal holds Board positions across the
Piramal Group & in other key organizations, universities and government bodies.

Geralyn S. Ritter is Vice President, Global Public Policy, at Merck & Co., Inc.,
responsible for public policy, government affairs and corporate responsibility matters.
She was previously Senior Vice President for International Affairs at the
Pharmaceutical Research and Manufacturers of America (PhRMA) and before that
Assistant General Counsel for international issues. Prior to joining PhRMA, Ms. Ritter
served as Trade Counsel at the Washington law firm of Covington & Burling, where
she represented clients on international trade and intellectual property matters. Ms.
Ritter also served for three years as Associate General Counsel for intellectual
property matters at the Office of the U.S. Trade Representative in the Executive
Office of the President. She represented the USA in the first IP case it filed under the
WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) at
the WTO in Geneva, as well as in the first such case filed against the USA. Ms. Ritter
has MA in International Studies from the School of Advanced International Studies
(SAIS) at Johns Hopkins University, a law degree from the Stanford University
School of Law, and a BA in economics and political science from Duke University.

Jeffrey D. Sachs is the Director of The Earth Institute, Quetelet Professor of
Sustainable Development, and Professor of Health Policy and Management at
Columbia University. He is also Special Advisor to UN Secretary-General Ban Kimoon
on the Millennium Development Goals. From 2002 to 2006, he was Director of
the UN Millennium Project. Sachs is President and Co-Founder of Millennium
Promise Alliance, a nonprofit organization aimed at ending extreme global poverty.
Professor Sachs is in the forefront of addressing the challenges of economic
development, poverty alleviation, and globalization, promoting policies to help
everyone benefit from expanding economic opportunities and wellbeing while
ensuring environmental sustainability. He has been a senior advisor to governments
worldwide, and has worked with international agencies, businesses, and
humanitarian organizations to forge new strategies for sustainable development. As
Director of the Earth Institute, Prof. Sachs leads a large-scale effort to harness
sciences including climatology, hydrology, engineering, economics, geography, and
public health to ensure sustainable development. Sachs is author of hundreds of
articles and many books, including the bestsellers Common Wealth and The End of
Poverty. Sachs is a member of the Institute of Medicine and is a Research Associate
of the National Bureau of Economic Research. He has twice been named among the
100 most influential leaders in the world by Time Magazine. He was awarded the
Padma Bhushan, a high civilian honor bestowed by the Indian Government, in 2007.
A native of Detroit, Michigan, Sachs received his B.A., M.A., and Ph.D. degrees at
Harvard University.

Julian Schweitzer is the Director, Health Nutrition and Population in the Human
Development Network of the World Bank and was previously Director of the Human
Development Sector in the South Asia Region of the World Bank, responsible for the
Bank’s operations in health, nutrition, population, education and social protection.
During his career in the Bank, he has also worked in the Middle East and North
Africa, Latin America and the transition economies of Europe, managing operations
in health, education, and social protection. He has also worked as the Operations
Director in the Bank’s East Asia and Pacific region and as the Bank’s Country
Director based in Russia. In South Asia, he developed sectoral approaches to
mobilize external financing. He strengthened the Bank’s regional HIV/AIDS
engagement with clients and external partners, and its advisory and financial roles.
He holds a Ph.D. from the University of London and has authored numerous articles
and essays on economic and human development.

Dr Robert Sebbag is currently Vice President for Access to Medicines at sanofiaventis.
In this role, Dr Sebbag participates in the development of the company’s
access to medicines strategy for the Southern Hemisphere. Prior to joining sanofiaventis,
Dr. Sebbag worked in Brussels for the European pharmaceutical industry
association (EFPIA), creating a communications platform for the pharmaceutical
companies operating in Europe. Before that, he was Senior Vice President
forCommunications for the vaccine company, Aventis Pasteur (today known as sanofi
pasteur). In addition to his activities within the pharmaceutical industry, Dr. Sebbag
also teaches public health courses within the Paris hospital system, focusing on
tropical parasitic diseases. Dr. Sebbag is active within the French Red Cross and has
participated in numerous health missions in the Southern Hemisphere. Dr. Sebbag is
a Medical Doctor with a specialty in tropical parasitic diseases and training in
psychiatry.

Bennett M. Shapiro, M.D. is a Partner at PureTech Ventures. Prior to this, he was
Executive Vice President of Merck Research Laboratories, responsible for all basic,
preclinical and external research activities worldwide. Earlier, he was Professor and
Chairman of the Department of Biochemistry at the University of Washington. He is
the author of over 120 papers on the molecular regulation of cellular behavior and the
cellular activations at fertilization. Shapiro has bachelor’s degree in chemistry from
Dickinson College and a doctor’s degree in medicine from Jefferson Medical College.
Following an Internship in Medicine at the University of Pennsylvania Hospital, he
was a Research Associate at the NIH, then a Visiting Scientist at the Institut Pasteur
in Paris, and returned to the NIH as Chief – Section on Cellular Differentiation in the
Laboratory of Biochemistry, prior to joining the University of Washington. He has
served on many institutional advisory boards and scientific review panels. Shapiro is
Chairman of Vascular Biogenics, Ltd., and a Director of Momenta Pharmaceuticals,
Celera, Protein Forest, Satori, and Elixir Pharmaceuticals. He also a Director of DNDi
and Chairman of the Drugs for Neglected Diseases initiative-North America.

Mae joined the Novartis Vaccines Institute for Global Health (NVGH) in Siena, Italy, in
July 2007 and is responsible for external collaborations, partnerships and licensing.
She has previous experience in building partnerships between industry and NGOs
and funders from working for 4 years at the Novartis Institute for Tropical Diseases
(NITD) in Singapore, where partnerships with the Wellcome Trust, the Grand
Challenges for Global Health, and the Global Alliance for TB Drug Development were
established. Mae came to Novartis in March 2000 after obtaining an MBA from
INSEAD (Fontainebleau, France) and has an engineering degree from Purdue
University in the USA. She is currently working on a Masters in International Health
(MIH) degree from the Swiss Tropical Institute and the TropEd Network on a part-time
basis.

Billy Tauzin became president and chief executive officer of the Pharmaceutical
Research and Manufacturers of America (PhRMA) in 2005, after long career in public
service career, including 13 terms representing the 3rd Congressional District of
Louisiana. First elected to the House in 1980 as a Democrat, he switched parties in
1995. In 1998, he joined with House Majority Leader Dick Armey to propose a
revamping of the tax code. He held several leadership positions in Congress,
including chairmanship of a Merchant Marine Subcommittee, and was Deputy
Majority Whip. More recently, he served as Chairman of the influential House
Committee on Energy and Commerce, which has jurisdiction over all interstate and
foreign commerce, including energy, telecommunications, health care, biomedical
research, consumer protection, the environment and travel and tourism. In this
capacity, he helped President George W. Bush win passage of a Medicare
prescription drug bill. He was also the original author of the Securities Litigation
Reform Act and the Cable Act – the only bills over the past decade to become law
despite a Presidential veto. Billy Tauzin began his public service career in the
Louisiana State Legislature where he served as Chairman of the House Natural
Resources Committee and Chief Administration Floor Leader. Billy Tauzin received a
Bachelor of Arts Degree from Nicholls State University in 1964 and a Law Degree
from Louisiana State University in 1967.

Mr. Williams became head of the Canadian pharmaceutical industry association
Rx&D after a successful career in provincial politics and community service. For
fifteen years, Mr. Williams represented the Montreal riding of Nelligan in the National
Assembly of Quebec. As a Liberal MNA, he led numerous public policy debates on
issues such as the role of government in research and development (R&D),
compensation for victims of contaminated blood, linguistic policy, access to services
for handicapped people, pre-hospital emergency services, and gambling. He is an
advocate for individual rights, and government services focused on the needs of its
citizens. During his tenure as parliamentary assistant to two Ministers of Health and
Social Services, Mr. Williams developed strategies for a more efficient and integrated
health care system. In addition, he spearheaded the development of an R&D policy
for the pharmaceutical sector. Prior to and during his political career, Mr. Williams
played a key role in numerous non-profit and community-based initiatives in areas
ranging from palliative care to human rights.

Mr. Zhang is Director of the Pharmaceutical Division of the Pharmaceutical & Biologic
Invention Examination Department of patent office of the State Intellectual Property
Office of the People’s Republic of China. After he graduated from Beijing University
of Traditional Medicine with a bachelor’s degree in medicine in 1991, he began to
work as a patent examiner at SIPO. In 2004, he obtained an LL.M from John
Marshall Law School and is now studying in Peking University for an MPA. He has
published numerous articles relating to IPR protection in the pharmaceutical field. He
is part of the PRC’s National Intellectual Property Strategy research group.